Please try another search
Zydus Lifesciences Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported revenue was INR 44,228 million compared to INR 40,499 million a year ago. Net income was INR 8,007 million compared to INR 5,225 million a year ago. Basic earnings per share from continuing operations was INR 7.92 compared to INR 5.1 a year ago. Diluted earnings per share from continuing operations was INR 7.92 compared to INR 5.1 a year ago. Basic earnings per share was INR 7.91 compared to INR 5.15 a year ago. Diluted earnings per share was INR 7.91 compared to INR 5.15 a year ago.For the six months, revenue was INR 95,984 million compared to INR 80,801 million a year ago. Net income was INR 18,876 million compared to INR 10,408 million a year ago. Basic earnings per share from continuing operations was INR 18.67 compared to INR 10.24 a year ago. Diluted earnings per share from continuing operations was INR 18.67 compared to INR 10.24 a year ago. Basic earnings per share was INR 18.65 compared to INR 10.21 a year ago. Diluted earnings per share was INR 18.65 compared to INR 10.21 a year ago.
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | 45052 | 43688 | 51396 | 46677 |
Gross Profit | 30367 | 28950 | 34652 | 28111 |
Operating Income | 8870 | 8797 | 13526 | 7926 |
Net Income | 7896 | 8007 | 10869 | 2966 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 258794 | 257564 | ||
Total Liabilities | 49385 | 60681 | ||
Total Equity | 209409 | 209409 | 196883 | 196883 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | ||||
Cash From Investing Activities | ||||
Cash From Financing Activities | ||||
Net Change in Cash |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review